Edition:
United Kingdom

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

21.00USD
17 Aug 2018
Change (% chg)

$-0.54 (-2.51%)
Prev Close
$21.54
Open
$21.53
Day's High
$21.60
Day's Low
$20.77
Volume
543,050
Avg. Vol
725,035
52-wk High
$27.32
52-wk Low
$7.20

Summary

Name Age Since Current Position

Behzad Aghazadeh

46 2017 Independent Chairman of the Board

Michael Pehl

53 2017 President, Chief Executive Officer, Director

Michael Garone

59 2017 Chief Financial Officer, Vice President - Finance

Morris Rosenberg

Chief Technology Officer

Brendan Delaney

2017 Chief Commercial Officer

Robert Iannone

2018 Head of Research & Development and Chief Medical Officer

Usama Malik

Chief Business Officer

Scott Canute

57 2017 Independent Director

Peter Hutt

83 2017 Independent Director

Khalid Islam

62 2017 Independent Director

Biographies

Name Description

Behzad Aghazadeh

Dr. Behzad Aghazadeh is Independent Chairman of the Board of the Company. He was Partner and Senior Analyst at Sio Capital Management from 2009 to 2011. Vice President and Senior Analyst at Bernstein Value Equities from 2006 to 2009. From 2000 to 2006, Dr. Aghazadeh was in the healthcare practice of Booz Allen (now a unit of PricewaterhouseCoopers), where he led major strategic and operational initiatives for pharmaceutical and biotechnology clients.

Michael Pehl

Mr. Michael F. Pehl has been appointed President, Chief Executive Officer, Director of the Company. He is our President and Chief Executive Officer, has more than 20 years of experience in hematology and oncology and has launched multiple blockbuster drugs in that space including Revlimid, Pomalyst, and Abraxane. Previously, Mr. Pehl spent 11 years at Celgene Corporation, serving as General Manager Germany, Vice President Central Europe, Head of Hematology Europe and subsequently as Head of Global Marketing and finally as President of Hematology & Oncology.

Michael Garone

Mr. Michael R. Garone has been appointed Chief Financial Officer, Vice President - Finance of the Company. He joined Immunomedics as Vice President, Finance and Chief Financial Officer in June 2016 and assumed the additional role of Principal Executive Officer in July 2017. Previously, from August 2007 through June 2016, he was the Chief Financial Officer of Emisphere Technologies, Inc., a commercial stage, specialty pharmaceutical company, where he also served as Corporate Secretary since October 2008 and as Interim Chief Executive Officer from February 2011 until September 2012. Before Emisphere, Mr. Garone served as Interim Chief Executive Officer and Chief Financial Officer of Astralis, Ltd. Prior to that, he served 20 years at AT&T, where he held several positions, including Chief Financial Officer of AT&T Alascom. Mr. Garone received an MBA from Columbia University and a BA in Mathematics from Colgate University.

Morris Rosenberg

Dr. Morris Z. Rosenberg is Chief Technology Officer of the Company. Over 28 years of biologics drug development experience Most recently, EVP of Development responsible for manufacturing, process development and supply chain management at Seattle Genetics.

Brendan Delaney

Mr. Brendan P. Delaney is Chief Commercial Officer of the Company. Mr. Brendan was most recently Vice President, U.S. Commercial Hematology Oncology at Celgene. In this role, Brendan oversaw a team of roughly 400 professionals across sales, marketing and strategic alliances. Notably, under Brendan's leadership, the revenue for the group grew to over $7 billion annually, representing a significant proportion of Celgene's global revenue. Prior to this role, Brendan held a series of other senior-level marketing roles at Celgene. Before coming to Celgene he was at Novartis for five years, serving in a number of U.S. and global marketing roles within the Company's oncology business unit. Over the course of his 22-year commercial career Brendan has been involved in the launch of nine new oncology products and indications.

Robert Iannone

Dr. Robert Iannone, M.D., M.S.C.E., is a Head of Research and Development and Chief Medical Officer of the Company. Iannone comes to Immunomedics from AstraZeneca/MedImmune where he oversaw the development of Imfinzi and was, most recently, Senior Vice President and Head of Immuno-oncology, Global Medicines Development. He joined AstraZeneca/MedImmune in July 2014 as Global Products Vice President. Prior to AstraZeneca/MedImmune, Dr. Iannone served as Executive Director, Clinical Research, and Section Head of Oncology at Merck Research Laboratories and was a development leader for Keytruda. Dr. Iannone received his M.D. from Yale University School of Medicine with Alpha Omega Alpha honors and a Master of Science in Clinical Epidemiology from the University of Pennsylvania School of Medicine. Dr. Iannone completed his Residency at Johns Hopkins Hospital, where he also served as Chief Resident for one year and completed his Pediatric Hematology and Oncology Fellowship. Dr. Iannone is the author or co-author of numerous articles in peer-reviewed journals and has served on the Biomarkers Consortium of the Cancer Steering Committee of the Foundation for the National Institutes of Health since 2011.

Usama Malik

Mr. Usama Malik is Chief Business Officer of the Company. He is Responsible for business development, corporate and portfolio strategy, and corporate transformation Global VP of Corporate Strategy, Innovation, and Digital Ventures at Pfizer Inc. Previously served as senior executive & executive advisor at Novartis, BMS, Lily, Schering, Intarcia, Zoetis, Danaher, Quest Diagnostics, Aetna among others.

Scott Canute

Mr. Scott A. Canute is Independent Director of the Company. Mr. Canute has served on the Boards of Directors of Akebia Therapeutics since August 2016, Proteon Therapeutics since July 2015, Flexion Therapeutics since March 2015, Oncobiologics Inc. since October 2011. He previously served as a Technology Advisory Board Member of Moderna Therapeutics from August 2013 to January 2016. Mr. Canute also served on the Boards of Directors of Allocure, Inc. from October 2012 to October 2014 and Inspiration Biopharmaceuticals, Inc. from September 2012 to September 2013. President of Global Manufacturing and Corporate Operations of Genzyme from 2010 until 2011. President, Global Manufacturing Operations of Eli Lilly and Company from 2004 to 2007.

Peter Hutt

Mr. Peter Barton Hutt is Independent Director of the Company. Mr. Hutt has served on the Boards of Directors of Flex Pharma, Inc. since 2014; Suneva Medical, Inc. since 2014; Moderna Therapeutics, Inc. since 2012; Selecta Biosciences, Inc. since 2010; Concert Pharmaceuticals, Inc. since 2007; and Q Therapeutics, Inc. since 2002. He previously served on the Boards of Directors of Seres Therapeutics, Inc. from 2013 to 2017; DBV Technologies S.A. from 2009 to 2015; BIND Biosciences, Inc. from 2008 to 2016; Living Proof, Inc. from 2007 to 2017; NanoMedical Systems, Inc. from 2007 to 2015; Xoma Corporation from 2005 to 2017; Pervasis Therapeutics, Inc. from 2004 to 2012; Ista Pharmaceuticals, Inc. from 2002 to 2012; and Momenta Pharmaceuticals, Inc. from 2001 to 2014.

Khalid Islam

Dr. Khalid Islam, Ph.D., is Independent Director of the Company. He is Managing Director of Life Sciences Management GmbH, since 2014; Co-Founder and Partner of Sirius Healthcare Partners GmbH, a Swiss life sciences company, in 2009; Founder of PrevABR LLC, an American clinical-stage therapeutics company, in 2010. Dr. Islam has served as Chairman of the Boards of Directors of Minoryx Therapeutics since 2016 and Fennec Pharma, Inc. since 2014. Dr. Islam was previously a member of the Boards of Directors of Oxthera AB from 2014 to 2017 and Karolinska Development from 2015 to 2017 and Molmed SpA from 2014 to 2016. He also served as Chairman of the Boards of Directors of PCovery Aps from 2011 to 2015 and C10 Pharma A/S from 2010 to 2014.

Basic Compensation